Setting the R&D Strategic Direction

1.1 Defining the Role of R&D in the Corporate and Business Strategy

The starting point for R&D strategy is a clear view of what the business expects R&D to accomplish. That sounds obvious, but leadership teams often move directly to questions about projects, budgets, laboratories, technologies, or headcount without first defining R&D’s economic and strategic role. As a result, the organization may optimize individual programs while leaving the overall portfolio misaligned with the enterprise strategy.

R&D can play several different roles. In one company, its primary mandate may be to create differentiated products that support premium pricing. In another, the most important contribution may be reducing manufacturing cost through process innovation. A third company may depend on R&D to establish a new technology platform that enables entry into an adjacent market. A mature software business may need engineering investment primarily to improve platform reliability, address technical debt, and protect retention before allocating significant capacity to new products. A biotechnology company may rely on R&D to generate a sequence of risk-adjusted clinical assets whose future value is only partly reflected in current revenue.

The role therefore needs to be defined in business terms rather than technical terms. Statements such as “be more innovative,” “develop breakthrough technologies,” or “accelerate the pipeline” are too broad to guide trade-offs. A useful role definition specifies how R&D is expected to create value and what types of outcomes matter most.

Executives should begin by connecting four layers of strategy:

1. Corporate direction: What businesses, markets, geographies, and capabilities will the enterprise emphasize over the planning horizon?
2. Business-unit strategy: How will each business compete, grow, defend margins, and differentiate its offering?
3. Innovation requirements: What product, process, technology, data, or scientific advances are necessary to make those strategies achievable?
4. R&D contribution: Which of those advances should be created, enabled, or orchestrated by the R&D organization?

This sequence prevents R&D planning from becoming an internally focused exercise. For example, if the corporate strategy calls for expansion into high-growth applications, R&D may need to prioritize application development, customer co-creation, and rapid prototyping rather than fundamental platform research. If the strategic priority is margin expansion, the R&D agenda may need to emphasize formulation simplification, product architecture, manufacturing yield, material substitution, or design-to-cost initiatives. The technical agenda should follow the business requirement.

Leaders should also distinguish between the role of R&D in defending the existing business and its role in creating future businesses. Defensive work includes regulatory compliance, quality improvements, technical support, cybersecurity, platform maintenance, obsolescence management, and mandatory product upgrades. These activities may not produce visible new revenue, but insufficient investment can create operational or competitive risk. Growth-oriented work includes new products, extensions, technology platforms, new indications, new applications, and entirely new business models. Both can be strategically important, but they should not be mixed together without explicit choices.

A practical method is to describe R&D’s role through a small number of value-creation missions. Typical missions include:

• Protect and extend core products or platforms.
• Enable defined growth opportunities in priority markets.
• Create distinctive technologies that strengthen competitive advantage.
• Improve cost, quality, sustainability, or manufacturability.
• Build strategic options in technologies likely to reshape the industry.
• Provide technical capabilities required for regulatory, safety, or customer obligations.

Each mission should be tied to an enterprise objective. If leaders cannot explain which strategic objective a major category of R&D spending supports, that spending deserves scrutiny.

The role definition must also recognize differences across businesses. A diversified company rarely needs one identical R&D model everywhere. A mature cash-generating division may require disciplined incremental development, while a newer growth platform may justify heavier investment and greater technical uncertainty. The corporate strategy should establish boundaries and allocation logic without forcing artificial uniformity.

Another important distinction is between R&D as an internal producer and R&D as an innovation orchestrator. Modern innovation strategies often depend on universities, suppliers, startups, contract research organizations, engineering partners, licensors, and acquisition targets. The strategic question is not simply what the internal organization can invent. It is which capabilities must be proprietary, which can be accessed externally, and where ownership creates genuine competitive advantage. This framing becomes important when later evaluating build, partner, license, or acquire choices.

The output of this work should be a concise statement of R&D’s role, supported by explicit value-creation missions and boundaries. That statement provides the test against which later portfolio decisions can be made. A technically impressive project that does not support the defined role may still be interesting, but it should not automatically command strategic funding.

1.2 Translating Growth, Margin, and Competitive Ambitions into R&D Priorities

Once the role of R&D is clear, leadership must translate corporate ambitions into a manageable set of R&D priorities. This is where strategy becomes operational. Growth targets, margin goals, market-share ambitions, or technology aspirations do not allocate engineering teams or laboratory capacity by themselves. They need to be converted into specific innovation requirements.

A useful starting point is to decompose each major business ambition into the technical outcomes required to achieve it. Consider a company targeting significant revenue growth in an adjacent customer segment. The R&D implications might include a lower-cost architecture, different product specifications, new certifications, software integration, redesigned packaging, or a technology partnership. If management instead wants to expand margins in the core business, the implications might include platform standardization, lower material cost, reduced manufacturing complexity, improved energy efficiency, or fewer product variants.

This translation should move from business outcome to innovation requirement to R&D response. The distinction is important because the first technical solution proposed is not necessarily the best one. For example, a growth target does not automatically imply developing a new product. The objective might be achieved more efficiently through a line extension, software enhancement, evidence generation, application development, licensing arrangement, or reuse of an existing platform.

For each strategic ambition, management should answer five questions:

1. What business outcome are we trying to create?
2. What customer, market, cost, or competitive barrier prevents us from achieving it today?
3. What technical or product advance would materially change that constraint?
4. What R&D capabilities and resources are required?
5. What evidence will demonstrate that the investment is working?

This exercise exposes strategic gaps quickly. A company may discover that its growth plan depends heavily on launches for which no funded development programs exist. Alternatively, it may find that the current R&D portfolio contains substantial activity unrelated to the stated strategy. Either finding is useful because it turns a general alignment discussion into an identifiable investment problem.

Growth ambitions should be translated with particular care. Leaders should identify how much expected growth must come from the existing portfolio, incremental innovation, adjacent offerings, new platforms, or new markets. If the commercial plan assumes a large contribution from products that do not yet exist, the R&D strategy needs to acknowledge the implied development risk, time horizon, and funding requirement. Conversely, if growth expectations can be met largely through existing products, it may be inappropriate to justify a major increase in speculative R&D simply because innovation is viewed positively.

Margin ambitions create a different set of priorities. R&D teams sometimes treat cost improvement as separate from innovation, yet technical decisions strongly influence material cost, manufacturing yield, service requirements, product complexity, cloud infrastructure cost, and lifecycle economics. An R&D strategy linked to margin improvement should identify the technical cost drivers that can realistically be changed and estimate the economic value of doing so.

Competitive ambition adds another layer. Leaders should be explicit about where technical differentiation truly matters. Not every feature needs to be superior, and attempting to lead on every product attribute wastes resources. The strategy should identify the few dimensions on which technical advantage changes customer choice, pricing power, adoption, switching costs, regulatory position, or cost structure. These become priority battlegrounds for R&D.

This analysis also requires explicit trade-offs. Suppose management wants faster launches, broader platform investment, improved reliability, lower development cost, and more breakthrough innovation while holding the R&D budget flat. Those objectives may all be desirable, but they are unlikely to be simultaneously achievable without stopping work elsewhere. A credible strategy identifies what will receive less attention.

One useful tool is an ambition-to-priority map. For each enterprise objective, document the required innovation outcome, key programs or capability themes, indicative investment level, time horizon, and measurable business impact. The map should remain at a strategic level; detailed project scoring comes later. Its purpose is to reveal whether the collection of R&D priorities is sufficient, coherent, and affordable.

Priorities should normally be expressed as choices rather than themes. “Artificial intelligence,” “digital,” “sustainability,” or “advanced materials” are themes. “Use artificial intelligence to reduce diagnostic turnaround time by 30 percent in the flagship platform” is closer to a priority because it specifies the business purpose. Strong R&D priorities indicate where innovation matters, why it matters, and what outcome leadership expects.

Finally, leaders should distinguish committed priorities from exploratory interests. A committed priority receives protected resources and senior attention. An exploratory interest receives enough funding to create evidence before a larger commitment is made. Treating every emerging technology as a strategic priority produces a portfolio that is broad but shallow. The discipline is to concentrate resources where the combination of strategic relevance, economic potential, technical plausibility, and timing is strongest.

1.3 Choosing the Right Innovation Horizon Mix: Core, Adjacent, and Transformational Bets

An R&D strategy must balance near-term business needs with investments whose value may emerge years later. The familiar distinction among core, adjacent, and transformational innovation provides a useful starting framework, but it should be applied as a decision tool rather than as a fixed allocation formula.

Core innovation: Investments that improve, extend, support, or defend existing products, platforms, processes, or customer propositions. Examples include product upgrades, cost reductions, performance enhancements, formulation changes, software releases, reliability improvements, and regulatory modifications.

Adjacent innovation: Investments that extend established capabilities into new products, customer segments, applications, technologies, or markets. These initiatives typically involve more uncertainty than core work because at least one dimension of the business model or technology is less familiar.

Transformational innovation: Investments intended to create materially new platforms, technologies, products, or businesses. They may involve new science, new technical architectures, unfamiliar customers, or significant uncertainty about commercialization. Their payoff can be substantial, but so can their failure rate and time to impact.

The purpose of dividing the portfolio into horizons is not to force every company into a standard percentage split. Appropriate allocation depends on industry dynamics, corporate ambition, technology maturity, financial position, and the economics of development. A pharmaceutical portfolio and an industrial equipment portfolio cannot be managed with the same horizon assumptions. Even within one company, the right mix may vary by business unit.

Management should begin with the strategic need for each horizon. Core investment is usually necessary to protect current earnings and customer relevance. Adjacent investment often supports medium-term growth. Transformational investment can create long-term options and protect against disruption. The question is how much exposure the business needs to each type given its strategic position.

Several factors should influence the horizon mix. A company facing rapid technology disruption may need a larger portfolio of transformational options than a company in a stable category. A business with an aging product line and a weak launch pipeline may need greater adjacent investment. A company struggling with quality, reliability, or customer retention may need to reinforce the core before funding a wide range of speculative programs. A highly leveraged organization with limited financial flexibility may choose fewer transformational bets while preserving inexpensive experiments that keep future options open.

Leaders should also assess the expected time profile of value. A portfolio can look attractive in aggregate yet contain a dangerous gap between the maturity of the current offering and the arrival of the next growth platform. Mapping expected technical milestones, launches, and economic contributions by year helps identify periods in which the portfolio lacks sufficient value creation.

The horizon framework is most useful when paired with differentiated management rules. Core initiatives often have better-understood economics and can be held to relatively precise cost, schedule, and commercial expectations. Adjacent initiatives require testing of assumptions about customers, applications, or channels. Transformational bets require staged learning because early forecasts may be highly unreliable. Using the same business-case standard for all three horizons either makes speculative work appear artificially precise or allows mature projects to escape normal economic discipline.

A practical approach is to define an investment logic for each horizon:

• Core: Fund when the initiative protects or improves an economically important franchise and can demonstrate a credible return, customer benefit, risk reduction, or cost advantage.
• Adjacent: Fund in stages as evidence strengthens regarding technical feasibility, customer demand, and commercial scalability.
• Transformational: Purchase learning and strategic options initially; increase commitments only when defined technical and market uncertainties are resolved.

Leaders must also guard against portfolio relabeling. Teams sometimes classify incremental work as transformational to protect budgets or describe speculative projects as strategic because conventional economics are weak. Definitions should therefore be operational. Classification should reflect the degree of technological and market novelty, not the enthusiasm of the project sponsor.

Stopping rules matter as much as entry criteria. An innovation portfolio becomes overloaded when programs move forward by default. Each horizon should have evidence thresholds that determine whether work accelerates, continues, pauses, changes direction, or stops. Early termination of a weak transformational concept is not a failure of innovation strategy; it is evidence that staged investment is functioning properly.

The final horizon mix should be discussed as a portfolio of strategic exposure. Leadership should understand how much current spending protects the core, how much supports medium-term growth, and how much creates future options. The goal is not balanced for its own sake. It is deliberate imbalance that reflects the company’s strategy, competitive environment, and capacity to absorb risk.

1.4 Establishing R&D Strategic Objectives, Principles, and Decision Criteria

Strategic direction becomes durable only when it can guide decisions after the strategy workshop has ended. R&D organizations face hundreds of choices during the year: whether to add resources to a delayed program, pursue a new technology, accept a customer request, continue an uncertain experiment, standardize a platform, outsource development, or stop a legacy project. Senior leaders cannot adjudicate every decision. The strategy therefore needs a small set of objectives, principles, and criteria that managers can apply consistently.

Strategic objectives define the outcomes R&D is expected to produce. They should be specific enough to shape priorities but broad enough to remain useful across multiple programs. Examples might include accelerating entry into two identified growth markets, increasing platform reuse across product families, improving the proportion of development spend reaching commercial launch, or building leadership in a particular technology domain.

Good objectives combine direction with measurable intent. “Improve innovation productivity” is insufficient because different leaders may interpret it differently. A stronger objective might be to reduce resources tied up in low-priority programs while increasing investment behind the highest-value platforms. The exact measures can be developed later, but the objective already indicates the required management action.

Strategic principles define how the organization will make trade-offs. They are especially valuable when attractive opportunities compete for the same resources. Effective principles are short, discriminating, and consequential. If a principle never changes a decision, it is probably too generic.

Illustrative principles include:

• Concentrate investment behind fewer platforms with enterprise-scale potential rather than distributing funding evenly across business units.
• Protect mandatory safety, regulatory, reliability, and cybersecurity work before allocating discretionary growth funding.
• Prefer reusable platforms and modular architectures when they can support multiple products without unacceptable performance compromise.
• Use partnerships when external capabilities provide faster access and proprietary ownership is not strategically necessary.
• Increase funding in stages as technical and commercial evidence improves rather than committing full lifecycle budgets at project launch.
• Stop programs when agreed evidence thresholds are not met, even when substantial historical spending has already occurred.

Decision criteria translate these principles into repeatable evaluation. The most useful criteria normally cover several dimensions rather than relying on a single financial metric. Strategic fit asks whether the initiative supports the defined business priorities. Customer or market value considers the importance of the problem solved and potential willingness to adopt or pay. Economic value assesses revenue, margin, cost reduction, or option value. Technical feasibility examines scientific or engineering uncertainty. Competitive advantage considers differentiation and defensibility. Timing addresses whether the opportunity will still matter when development is complete. Resource fit evaluates scarce skills, facilities, data, equipment, and management attention.

Criteria should be designed to reveal differences among programs, not to create a mechanical score that disguises judgment. A weighted model can be helpful when comparing many initiatives, but leaders should avoid false precision. A project scoring 7.8 should not automatically defeat one scoring 7.6 if the latter creates a strategically critical capability. Quantitative scoring is an input to decision-making, not a substitute for executive judgment.

The organization should also identify non-negotiable gates. Some initiatives should fail before full scoring if they conflict with safety requirements, regulatory constraints, strategic boundaries, intellectual-property rules, or minimum economics. Conversely, certain mandatory investments may need to proceed despite low conventional returns because they protect license to operate or prevent material enterprise risk.

Decision criteria should differ where uncertainty differs. A mature product extension may require a robust financial case and credible launch forecast. An early platform experiment may be justified by the value of learning, provided the initial investment is small and the experiment resolves an important uncertainty. Applying one standard to both creates poor decisions.

It is also useful to establish evidence of expectations by development stage. At an early stage, the central question may be whether a technical concept is feasible. Later, leaders may require evidence of customer value, manufacturability, regulatory pathway, scalability, unit economics, or commercialization readiness. Increasing evidence requirements as investment grows creates a rational relationship between uncertainty and financial commitment.

Strategic objectives and principles should be tested against real portfolio decisions before they are finalized. Select several difficult cases, including a politically supported legacy program, a high-risk new technology, a mandatory core investment, and a promising adjacent opportunity. Ask whether the proposed principles lead leadership toward choices it actually considers strategically sound. If every initiative passes, the criteria are too permissive. If transformative options are systematically eliminated, the criteria may be too biased toward near-term certainty.

Once agreed, these objectives and principles should become the common language of portfolio reviews, budgeting, business cases, and program governance. Consistency matters. If leaders approve exceptions whenever a powerful sponsor objects, the organization learns that stated strategy is less important than internal influence. The credibility of R&D strategy is established through repeated resource decisions.

1.5 R&D Strategy Charter and Leadership Alignment Checklist

The strategic direction should ultimately be captured in a concise R&D strategy charter. The charter is not a substitute for detailed analysis. Its purpose is to record the decisions that analysis has produced so that executives, business-unit leaders, R&D teams, and adjacent functions work from the same mandate.

A strong charter can often fit on two or three pages. It should be specific enough to resolve recurring questions but short enough to be used in actual management discussions. Long strategy documents are useful as analytical records; they are less effective as decision tools.

Recommended R&D Strategy Charter

The following structure can be adapted to the company’s planning process:

• Business context: Summarize the corporate priorities, market changes, technology shifts, performance issues, or investment constraints that make the R&D strategy necessary.
• Role of R&D: State how R&D is expected to create value for the enterprise and which strategic missions it must fulfill.
• Priority outcomes: Identify the small number of business and innovation outcomes that should receive disproportionate attention over the planning horizon.
• Innovation horizon intent: Describe the intended role of core, adjacent, and transformational investment and any material changes from the current mix.
• Technology and capability themes: Identify capabilities that must be strengthened, accessed externally, or deliberately deprioritized.
• Investment principles: State the rules governing concentration of resources, staged funding, partnership choices, and program continuation or termination.
• Decision boundaries: Clarify important constraints, including areas the organization will not pursue, minimum evidence expectations, and decisions requiring executive escalation.
• Measures of progress: Identify a limited number of indicators that will show whether the strategy is producing the intended portfolio and business outcomes.
• Governance ownership: Name the executives or forums responsible for maintaining the strategy, resolving trade-offs, and approving significant changes.

The charter should distinguish between decisions already made and questions that remain open. This prevents teams from treating unresolved issues as settled strategy. For example, leadership may agree that external partnerships should play a larger role while still needing to determine which technology domains are suitable for licensing. Recording that distinction helps sequence follow-on analysis.

Leadership alignment is more demanding than obtaining approval in a meeting. Executives may agree with general strategy language while holding different assumptions about funding, risk, or the programs that will be stopped. The most reliable test of alignment is whether leaders make consistent choices when presented with specific trade-offs.

Leadership Alignment Checklist

Before moving into detailed portfolio prioritization and implementation, the leadership team should be able to answer “yes” to the following questions:

• Do we agree on the business outcomes R&D is expected to support?
• Do we understand which parts of the corporate strategy depend materially on successful R&D execution?
• Have we identified the technical, product, process, or capability advances required to deliver those outcomes?
• Do we agree on which R&D missions are most important and which are secondary?
• Have we defined the intended balance among protecting the core, pursuing adjacent growth, and creating transformational options?
• Do we understand the level of uncertainty and time to value associated with each horizon?
• Have we agreed on the strategic areas where investment should increase, remain stable, or decline?
• Are we willing to stop or reduce lower-priority programs to fund the priorities?
• Do we agree on which capabilities must be owned internally and where external access is acceptable?
• Have we established principles for staged investment and evidence-based continuation decisions?
• Are the criteria for evaluating R&D opportunities sufficiently clear to guide business-unit and functional leaders?
• Have we identified any mandatory investments that should be treated differently from discretionary innovation?
• Do we know which decisions can be made within R&D and which require business-unit or executive approval?
• Have we defined how progress against the strategy will be reviewed and when the strategy itself will be refreshed?
• Can each senior leader explain the strategy in substantially the same terms?

Any “no” answer is a signal that the strategy may not yet be ready for detailed resource allocation. The issue does not necessarily require another large strategy process. Often the remaining disagreement can be resolved through a focused decision session built around specific alternatives and their consequences.

Consultants and internal strategy teams should make disagreements visible rather than smoothing them over. A chief technology officer may favor a major platform investment while business-unit leaders prefer near-term product extensions. Finance may challenge the level of speculative spending. Commercial leadership may question whether the proposed innovations solve customer problems that matter. These tensions are legitimate. The purpose of the strategic-direction process is to resolve them explicitly before they emerge indirectly through annual budgeting, staffing negotiations, or project-level escalation.

A useful alignment session presents the leadership team with a small number of concrete portfolio implications. For example: “If we protect funding for the new technology platform, these three lower-priority extensions will be delayed,” or “If we maintain all currently committed programs, there is insufficient capacity to support the stated growth initiative.” Such choices force leaders to confront resource constraints and distinguish genuine priorities from aspirations.

The charter should be approved by the executives who control the resources required to implement it, not only by the R&D leader. Depending on the organization, that may include the chief executive officer, chief financial officer, business-unit presidents, chief technology or scientific officer, product leadership, and selected commercial or operations executives. Their involvement matters because implementation will require trade-offs across budgets, people, facilities, business units, and external partnerships.

Once approved, the charter becomes the reference point for the next stages of R&D strategy. Portfolio prioritization should test each major program against the agreed strategic role and decision criteria. Investment planning should translate priorities into budget and headcount. Technology and capability strategy should determine what the organization must build or access. Roadmapping should sequence the selected investments. Governance should ensure that evidence is reviewed and resources are reallocated as conditions change.